Key result
Congestive heart failure mortality is attributable to dysrhythmic sudden death in up to 50% of cases, with the roles of amiodarone and implantable cardioverter-defibrillators continuing to evolve.
Why the study?
What is the evolving role of amiodarone and implantable cardioverter-defibrillators in managing ventricular dysrhythmias and sudden death mortality in patients with congestive heart failure?
What is the evolving role of amiodarone and implantable cardioverter-defibrillators in managing ventricular dysrhythmias and sudden death mortality in patients with congestive heart failure?
This review highlights the significant contribution of sudden death to heart failure mortality and discusses the evolving therapeutic roles of amiodarone and ICDs in its management.
No takes yet. Share an insight, caveat, or question.
Emphasizes arrhythmia risk in HF care; leaves open refined amiodarone-ICD indications amid therapeutic advances.
Leier et al. (2000) conducted a review in Congestive heart failure. Amiodarone and implantable cardioverter-defibrillator was evaluated. Congestive heart failure mortality is attributable to dysrhythmic sudden death in up to 50% of cases, with the roles of amiodarone and implantable cardioverter-defibrillators continuing to evolve.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: